Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for October 2012
October 1, 2012
- Updated Results from Phase 2b/3 GALAXY Trial Show Promising Improvement in Survival from the Addition of Ganetespib to Docetaxel in Second-Line Non-Small Cell Lung Cancer
- ImmunoGen, Inc. Announces Overall Survival Data Reported for Trastuzumab Emtansine (T-DM1) Phase III EMILIA Trial
- Lilly Releases Phase II Results for Monoclonal Antibody Ramucirumab in Lung Cancer
- AVEO and Astellas Announce New Data Presented at ESMO 2012 Congress Demonstrating the Safety and Tolerability Profile of Tivozanib in Patients with Advanced Kidney Cancer
- Exelixis Announces Data Presentation for GDC-0973 (XL518)
- 3-V Biosciences To Present Data on HCV Product Candidates at the American Association for the Study of Liver Disease Annual Meeting 2012
- Genentech's Trastuzumab Emtansine (T-DM1) Significantly Extended Survival in People With Aggressive Form of Breast Cancer
- Vertex Announces Presentation of New Data from Hepatitis C Development Program at AASLD Annual Meeting
- Tasquinimod Biomarker Phase II data presented at ESMO 2012
- Head-to-head study of GSK?s Votrient (pazopanib) vs sunitinib in advanced renal cell carcinoma meets primary endpoint; findings presented at ESMO 2012 Congress
- Merck to Present New Data for VICTRELIS (boceprevir) and MK-5172 at The American Association for the Study of Liver Diseases 2012 Annual Meeting
- Medivir Announces That Simeprevir (TMC435) Data Will Be Presented at the Upcoming AASLD Meeting
- BioAlliance Pharma SA: Presentation of Phase I clinical results with AMEP® biotherapy in the treatment of metastatic melanoma
- New Hepatitis C Data from Boehringer Ingelheim to be Presented at AASLD Annual Meeting
- CytRx's Aldoxorubicin Clinical Data Presented at the ESMO 2012 Congress
- MOLOGEN AG: Updated data on renal cancer therapy MGN1601 with further improved results
- Epizyme Publishes Landmark Data on Personalized Therapeutics for Lymphomas
- Soligenix Announces Presentation of OrbeShield Data at Annual Radiation Research Society Meeting
- Acacia Pharma Announces Positive Results From Phase Iia Nausea & Vomiting Study in Cancer Patients
- Study Affirms Safety of HPV4 Vaccine for Adolescents and Young Women in Routine Clinical Care
- Aragon Pharmaceuticals Announces Clinical Results from Ongoing Phase II Trial Confirming Robust Anti-Tumor Activity and Tolerability of ARN-509 in Three Different Patient Populations of Castration Resistant Prostate Cancer
October 2, 2012
- Studies assess linagliptin treatment in adults with type 2 diabetes (T2D), as well as add-on to basal insulin therapy
- Genzyme Phase 3 Study of Oral Compound Eliglustat Tartrate for Gaucher Disease Meets Primary Endpoint
- Lilly and Boehringer Ingelheim Present Health Outcomes Data for Investigational Novel Basal Insulin Analogue
- ELIQUIS (apixaban) Demonstrates Consistent Reductions in Stroke and Systemic Embolism, Major Bleeding and Mortality Compared to Warfarin in Patients with Nonvalvular Atrial Fibrillation at Varying Risk for Stroke and Bleeding
- Provectus Pharmaceuticals Presents Final Phase 2 Melanoma Data at ESMO 2012
- First Results from Phase 3 CANVAS Trial Show Canagliflozin as Add-on Therapy to Insulin Lowered Blood Sugar Levels in Patients with Type 2 Diabetes at an Elevated Risk for Cardiovascular Disease
- Athersys Reports on Progress in Phase 2 Study of MultiStem for Ischemic Stroke
- ABRAXANE Meets Primary Endpoint of Progression-Free Survival in Phase III Chemotherapy-Naïve Metastatic Melanoma Study
- Pooled analysis demonstrated reductions in systolic blood pressure with empagliflozin, an investigational SGLT-2 inhibitor, independent of changes in blood glucose and weight in adults with type 2 diabetes
- Cellectis Publishes Results Paving the Way for New Therapeutic Approaches against Cancer and Genetic Diseases
- Amarantus BioSciences Announces Landmark MANF Genomics Publication
- Receptos to Present at the 10th Annual Discovery on Target Conference
- AVEO Announces Detailed Results of Exploratory Phase 2 Study Evaluating Ficlatuzumab in First-Line Patients with Advanced Non-small Cell Lung Cancer; New Data Presented at ESMO
- Promising Data Presented on GenVec RSV Program
- Merrimack Pharmaceuticals' Therapies Show Promise In Certain Advanced Breast, Gastric And Gynecologic Cancers
- Popular Migraine Medicine Quickly Absorbed When Delivered With Novel Breath Powered OptiNose Bi-Directional Nasal Technology, New Comparative Data Demonstrates
October 3, 2012
- Noven Announces Positive Phase 3 Data Results for Investigational Low-Dose Nonhormonal Therapy for the Treatment of Vasomotor Symptoms Associated with Menopause
- Novartis Data at EASD From 45,000-Patient Study Demonstrate Real-World Effectiveness of Galvus in Patients With Type 2 Diabetes
- Phase IIb Data Showed Merck's Investigational Once-Weekly DPP-4 Inhibitor MK-3102 Significantly Lowered Blood Sugar in Patients with Type 2 Diabetes
- Study Finds Estrogen Therapy Improves Depression and Anxiety in Recently Menopausal Women Without Adverse Cognitive Effects
October 4, 2012
- Onconova Presents Positive Clinical Trial Results for Radiation Injury Protector Ex-RAD
- Hormone Therapy Has Many Favorable Effects in Newly Menopausal Women: Initial Findings of the Kronos Early Estrogen Prevention Study (KEEPS)
- Duchenne Muscular Dystrophy Is Closer to a Treatment With New Results From Sarepta Therapeutics; Cure Duchenne Early Supporter of Study
- Durata Therapeutics Presenting Two Abstracts Concerning Dalbavancin at IDWeek 2012
- Pfizer Announces Top-Line Results Of Prevenar 13 Phase 3 Trial In Adults 18 To 49 Years Of Age
October 5, 2012
- Collegium Announces Poster Presentation for Oxycodone DETERx, a Tamper-Resistant, Extended-Release Opioid at 6th Annual Pain Therapeutics Summit
- Ferrer Successfully Completes An Absorption, Tolerability and Safety Study in Juveniles As Young As Two Months of Age for Novel Antibacterial Compound Ozenoxacin
- Shionogi-Viiv Healthcare Announces Completion of Initial Clinical Registration Package for Dolutegravir in HIV
- Multiple miRNA Markers Associated with Angiogenesis and Tissue Injury Repair Expressed in Cytori's Cell Therapy
- XenoPort Reports Favorable Metabolism and Pharmacokinetics of XP23829, a Novel Fumaric Acid Ester, in Phase 1 Trial
- ViroPharma Presents New Cinryze (C1 Esterase Inhibitor [human]) Data On Site Of Care And Adherence At The 2012 Academy Of Managed Care Pharmacy Educational Conference
October 8, 2012
- EXPAREL as the Foundation of a Multimodal Regimen Achieves Statistical Significance in All Primary Endpoints, Including a 60 Percent Reduction in Length of Hospital Stay
- New Clinical Study from Rational Therapeutics Doubles Response Rate in Patients with Advanced Lung Cancer; Personalized Treatment for Lung Cancer Comes of Age
- GTx to Present Scientific Poster Presentations on Enobosarm to Prevent and Treat Muscle Wasting in Cancer Patients
- Progenra's Novel USP7 Inhibitors are Shown to Exert Multiple Anti-Tumor Effects
- New Data Presented at the 28th ECTRIMS Congress Showcase Teva's Ongoing Commitment to Multiple Sclerosis Research
- Journal of Clinical Oncology Publishes Phase III Results of Zaltrap (Aflibercept) VELOUR Study in Previously Treated Metastatic Colorectal Cancer
- Trevena Completes Phase 2a Study of TRV027 in Patients with Advanced Heart Failure
- Lilly Announces Detailed Results of the Phase 3 Solanezumab EXPEDITION Studies Following a Presentation of the Independent Analyses by the Alzheimer's Disease Cooperative Study (ADCS)
- Cempra, Inc. Announces Results of Intravenous Solithromycin Phase 1 Study
- Putting a block on neuropathic pain before it starts
- Dr. Eva Feldman, Principal Investigator, To Update Interim Data On Neuralstem ALS Trial
- Nuvilex Reports Additional Safety and Efficacy Data From Second Phase 2 Pancreatic Cancer Trial
- Cempra, Inc. Announces Positive Top-Line Results from Solithromycin Phase 2 Clinical Trial in Patients with Uncomplicated Urogenital Gonorrhea
- Inovio Pharmaceuticals' Synthetic Vaccines Delivered with Minimally Invasive Skin Electroporation Technology Generate Potent Immune Responses
- New Model Compares Economic Value of Subcutaneous Immunoglobulin Therapy with Intravenous Immunoglobulin
- Study Supports Efficacy, Safety of Hizentra in Japanese Patients with Primary Immunodeficiency Disease
October 9, 2012
- Cytheris Announces Publication in Blood Demonstrating CYT107 Reverses Lymphopenia and Increases Virus-Specific Immunity Post Stem Cell Transplantation
- Study Shows Benefits, Drawbacks, for Women's Incontinence Treatments
- BioLineRx Announces New Analysis of EAGLE Phase IIb Study Showing a Significantly Greater Beneficial Effect of BL-1020 on Cognitive Function in Schizophrenia Patients
- NanoViricides Oral FluCide Drug Candidate Dramatically Reduced Virus Load and Lung Damage Pathology in the Lungs of Animals Given Lethal H3N2 Influenza Virus Infection, and was Significantly Superior to Oseltamivir
- Study Supports Efficacy, Safety of Hizentra in Japanese Patients with Primary Immunodeficiency Disease
- Data from Investigator-Initiated Phase 2 Study of Eculizumab (Soliris) in Patients with Severe Relapsing Neuromyelitis Optica (NMO) Presented at the American Neurological Association (ANA) Annual Meeting
- New point of focus found for the treatment of Rheumatoid Arthritis and other autoimmune diseases
- MedImmune To Present Four Flu Abstracts At The Influenza Vaccines For The World Conference
- Nymox NX-1207 Prostate Cancer Trial Receives Second Positive Interim Safety Review From Independent Data Monitoring Committee
- Immunovaccine Reports Positive Interim Results from Phase I Study of Ovarian Cancer Vaccine Candidate, DPX-Survivac
- Canyon Pharmaceuticals' DESIR-ABLE Study Completed
- Dr. Eva Feldman, Principal Investigator, Updates Interim Data On Completed Neuralstem ALS Phase I Trial
- Results of Lymphoseek Phase 3 Clinical Trials in Melanoma Published in Annals of Surgical Oncology
- Receptos to Deliver Scientific Presentations about RPC1063 at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
- Genzyme to Present New Data from AUBAGIO and LEMTRADA Clinical Development Programs at ECTRIMS
- OncoSec Medical to Present Data at Two Upcoming Conferences
- Sophiris Bio Announces 12 Month Follow-Up Data from Phase 2b TRIUMPH Clinical Trial of PRX302 in Patients with Benign Prostatic Hyperplasia
October 10, 2012
- Teva to Present Positive Data for Glatiramer Acetate 40 mg/1 ml Given Three Times Weekly for Relapsing-Remitting Multiple Sclerosis
- AMPYRA Two-Year Safety Data Presented at 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
- Aeterna Zentaris: Phase 3 Results for AEZS-130 in AGHD to be Presented at Upcoming GRS and IGF Society Congress
- Biogen Idec's Commitment to MS Demonstrated Through Significant Scientific Data Being Presented at the 28th ECTRIMS
- Summit Announces Positive Phase 1 Trial Results for Smt C1100 for Treatment of Duchenne Muscular Dystrophy
- Outcome of Global Phase III (EPPIC) Studies
- Actinium Pharmaceuticals Announces Presentation for Actimab-A, a Novel Targeted Immunotherapy for Acute Myeloid Leukemia at the 8th Annual Hematologic Malignancies 2012 Conference
- Researchers to Present Data on Soliris (eculizumab) as a Treatment for Patients with aHUS and STEC-HUS at ASN Annual Meeting
- Inovio Pharmaceuticals' Cancer Vaccine Demonstrates for 1st Time that a DNA-Based Therapeutic Vaccine Can Produce Immune Responses to Kill Target Cells
- Neuralstem To Present Preclinical Data At Neuroscience 2012, 42nd Annual Meeting Of The Society For Neuroscience
- Gencaro Pharmacogenetic Effect Paper Published in Peer Reviewed Journal PLOS ONE
- Proteostasis Therapeutics to Present Data at Two Upcoming Scientific Meetings
October 11, 2012
- TYSABRI (natalizumab) Data at ECTRIMS Reaffirm Positive Effects of Treatment for People with Relapsing Forms of MS
- Acceleron and Collaborators Present Data on Potential Biomarkers for Metastatic Breast Cancer and Head and Neck Cancer at the "2012 Markers in Cancer" Conference
- Pfizer Announces Top-Line Results From A Phase 3 Long-Term Safety Study Of ALO-02:
October 12, 2012
- New Data from Phase 3 Studies Provide Additional Evidence Supporting Treatment Effect for Oral BG-12 (Dimethyl Fumarate) in Multiple Sclerosis
- Impax Pharmaceuticals Announces Extension of Rytary FDA Review Date to January 21, 2013
- New analysis indicates that Novartis drug Gilenya shows significant early effect on reducing brain volume loss at 6 months
- Genzyme Presents Second Phase III Study of Once-daily Oral Augagio (teriflunomide) Confirming Significant Impact on Disability
- Second Phase 2 Trial Of Telotristat Etiprate Shows Positive Results In Carcinoid Syndrome
- Updated Phase 2 Survival Data of Cyclacel's Sapacitabine for MDS Presented at The Eighth Annual Hematologic Malignancies 2012 Conference
- Islet Sciences Announces Publishing of Study Results of Production and Function of IL-12 in Islets and Beta Cells in Diabetologia
- HPV Vaccination Does not Lead to an Increase in Sex
- Targacept Scientists to Present at Neuroscience 2012
- Data from Phase 2 Combination Study of VX-809 and Ivacaftor in People with Cystic Fibrosis Who Have the Most Common Genetic Mutation (F508del) Presented at North American Cystic Fibrosis Conference
- YM BioSciences Reports CYT387 Phase I/II Results Selected for Oral Presentation at ASH2012 Conference
October 15, 2012
- Genkyotex's First in Class NOX Inhibitor GKT137831 to Be Presented at Kidney Week
- Cell Therapeutics' Unique Orally Available, Multi-Kinase (JAK2, FLT3, c-Fms) Inhibitor CT-1578 Demonstrates Ability to Prevent the Onset of Rheumatoid Arthritis and Potency in Treating and Reversing Bone and Cartilage Damage In Preclinical Models
- Merck Researchers Present BMD Data from a Phase II Study of Odanacatib, Merck's Investigational Cat-K Inhibitor for Post-Menopausal Osteoporosis
- Lilly Announces Positive Results For Ramucirumab as Single Agent in Phase III Gastric Cancer Trial
- Amgen Presents Several Sub-Analyses At ASBMR From The Ongoing Open-Label Extension Study Of The Pivotal Phase 3 Prolia Fracture Trial
- Civitas Therapeutics to Present Positive Clinical Study Results for CVT-301 at Sixth Annual Parkinson's Disease Therapeutics Conference, Sponsored by The Michael J. Fox Foundation for Parkinson's Research
- NanoBio Announces Data Presentation on its Nanoemulsion Adjuvanted RSV Vaccine at IDWeek 2012
- Nektar Presents Positive Preclinical Data for NKTR-171, A Novel Sodium Channel Blocker to Treat Neuropathic Pain, at 41st Annual Meeting of the Society for Neuroscience
- Significant Recovery Of Motor And Neurological Functions In Ischemic Stroke Rats With Neuralstem NSI-566 Cells
- Cyclacel's Sapacitabine Nearly Doubles Expected Survival of Elderly Patients With MDS After Front-Line Therapy Failure
- Abbott's Investigational Interferon-Free Hepatitis C Treatment Regimen Achieved SVR12 (Observed Data) Rates in 99 Percent of Treatment-Naive and 93 Percent in Prior Null Responders for Genotype 1 Patients in Phase 2b Study
- New Data From REPLACE Study Show Initiation of Bone Remodeling for Natpara-Treated Patients with Hypoparathyroidism
- Lilly Announces New Data Further Exploring Mechanistic Differences Between FORTEO (teriparatide [rDNA origin] injection) and Zoledronic Acid
- Unigene's Oral PTH Program Featured at ASBMR 2012 Annual Meeting
- Civitas Therapeutics to Present Positive Clinical Study Results for CVT-301 at Sixth Annual Parkinson?s Disease Therapeutics Conference, Sponsored by The Michael J. Fox Foundation for Parkinson?s Research
- Depomed Announces Serada NDA Acceptance and FDA Advisory Committee Meeting
- Tasimelteon Restores Daily Cortisol Rhythms in Blind Patients with Non-24-Hour Disorder
- HPV Vaccination Not Associated with Increased Sexual Activity Among Girls
October 16, 2012
- BioLineRx Announces Successful Completion of Pre-Clinical Development for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
- PROLOR Biotech Announces Positive Results From Preclinical Toxicology Study Of Its Reversible-Pegylation Platform Technology
- Tarsa Therapeutics Reports Positive Results From Phase II Trial Of Its Oral Calcitonin In Prevention Of Post-Menopausal Osteoporosis
- A.P. Pharma Announces PDUFA Action Date for APF530 New Drug Application Resubmission
- ArQule and Daiichi Sankyo Reach Agreement with FDA on Special Protocol Assessment for Phase 3 Trial of Tivantinib in Hepatocellular Carcinoma
- New Study With Chantix/Champix (varenicline) Tablets Suggests Favorable Benefit-Risk Profile In Adult Smokers With Major Depressive Disorder
- Biotron Limited to report new clinical data from BIT225 Hepatitis C Phase 2a trial in a late-breaking presentation at the AASLD 2012 annual conference
- OrbusNeich's COMBO Dual Therapy Stent to be Featured in Multiple Clinical Data Presentations Next Week at TCT 2012
- Brain Training Shown Effective for HIV-related Cognitive Problems
- INTAC - Grunenthal Group presents data demonstrating the strength of its tamper resistant technology at the American Association of Pharmaceutical Science Annual Meeting and Exposition.
- Beneficial Effects of Anatabine Supplementation in an Animal Model of Multiple Sclerosis Presented at Neuroscience 2012
- Bristol-Myers Squibb to Present New Data Demonstrating Company's Continuing Commitment to Research and Development in Liver Disease at The American Association for the Study of Liver Diseases (AASLD) Annual Meeting
- AB Science confirms the filing for the Marketing Authorization Application to the European Medicines Agency of Masitinib in the treatment of Pancreatic Cancer
- Wilex AG Announces Results of Phase III Ariser Study With Rencarex in Clear Cell Renal Cell Carcinoma
- Micell Technologies Announces Clinical Data Presentations at TCT 2012
- FDA Advisory Committee Unanimously Recommends Approval of Gattex (teduglutide) for Adults with Short Bowel Syndrome (SBS)
- Chiesi Reports Successful Completion First-in-Man Phase 1 Study With Novel Inhaled PDE4 Inhibitor
- Virginia Commonwealth University Scientists Report Anti-Inflammatory Effect of Aradigm's Inhaled Liposomal Ciprofloxacin
- MAP Pharmaceuticals Resubmits New Drug Application to FDA for LEVADEX Orally Inhaled Migraine Drug
October 17, 2012
- Pfizer Announces Top-line Results From Phase 3 Trial Of INLYTA (axitinib) In Treatment-Naïve Patients With Advanced Renal Cell Carcinoma
- Bayer to Present Data on Investigational Pulmonary Hypertension Compound at CHEST 2012
- Cebix Announces Positive Results of ERSATTA Phase 1/2 Trial Targeting Peripheral Neuropathy in Type 1 Diabetics
- Affymax and Takeda Announce OMONTYS Data Presentations at the American Society of Nephrology Kidney Week 2012
- Nabi Biopharmaceuticals Announces Results of Nicvax Phase II Study in Combination With Varenicline
- NIH Study Shows Drug Fails to Prevent Preterm Birth in High Risk Group
- New Study Shows Superior Dissolution Performance of Capsugel?s Thermogelled HPMC Capsules
- XBiotech Announces Progress in Clinical Development of Treatment for Psoriasis
October 18, 2012
- ALIMTA Extends Survival in Continuation Maintenance Setting for Specific Lung Cancer Patients
- Ampliphi Presents Encouraging Pre-Clinical Data on the Use of Phage-Based Therapies to Treat Bacterial Lung Infections
- Sanofi Pasteur Announces Application for New Four-Strain Influenza Vaccine Accepted by FDA for Review
- Biogen Idec Receives Notification of PDUFA Date Extension
- Study Shows Elevated Risk of Blood Clots and Arterial Blockage in Women Taking Birth Control Pills Containing Drospirenone
October 19, 2012
- Clinical Trials Show Theramine is Effective at Reducing Inflammation Associated with Chronic Back Pain
- New Study Shows Reprogrammed Amniotic Fluid Cells Could Treat Vascular Diseases
- Genticel announces positive data from its phase I trial in women infected with high-risk HPV before appearance of cervical lesions
- FDA Advisory Committee Recommends Kynamro for Homozygous Familial Hypercholesterolemia
- FDA Advisory Committee Recommends KYNAMRO for Homozygous Familial Hypercholesterolemia
October 22, 2012
- Bayer's Investigational Riociguat Meets Primary Endpoint in Phase III Study in Patients with Pulmonary Arterial Hypertension (PAH)
- Rhythm Announces Positive Phase 1 Results for Ghrelin Prokinetic RM-131
- Sanofi Pasteur Presents Phase III Data for Investigational Quadrivalent Influenza Vaccine
- New One-Year Phase 3 Study Results Show Anti-TNF SIMPONI Maintained Clinical Response In Treatment Of Moderately To Severely Active Ulcerative Colitis
- Health Canada Approves New Drug Submission for Cinryze (C1 inhibitor [human])
- CEL-SCI Corporation Announces Results of Interim Review of Data from Its Ongoing Phase III Head and Neck Cancer Trial by Independent Data Monitoring Committee (IDMC)
- Actelion Submits a New Drug Application to the FDA for Macitentan (Opsumit) for the Treatment of Patients With Pulmonary Arterial Hypertension
October 23, 2012
- Phase 3 Study Evaluates Two Investigational Hormone-Releasing IUDs for Prevention of Pregnancy for up to Three Years
- OncoSec Medical Incorporated Reports Positive Preliminary Efficacy and Safety Results from Phase II Study of ImmunoPulse in Merkel Cell Carcinoma Patients
- Results from Five Phase III Studies Presented for GSK's Two Candidate Quadrivalent Influenza Vaccines
- New Study Demonstrates that a Lower Carbohydrate and Lower Sugar Diet Reduces the Risk of Cognitive Impairment
- SARcode Bioscience Announces Positive Topline Results from Phase 3 Dry Eye Study of Lifitegrast
- Sleep Apnea Can Reduce Severity Of Cardiac Injury During A Heart Attack, According To Montefiore Study
- The Boston Scientific PROMUS Element Platinum Chromium Stent Demonstrates Positive Outcomes in Patients with Long Coronary Lesions
- Medgenics Announces EPODURE to be Presented in Poster Session at the American Society of Nephrology's Kidney Week 2012
- Ferring Announces FDA Acceptance of NDA Filing for Controlled Release Misoprostol Vaginal Insert for Decreasing Time to Vaginal Delivery in Women
- Teva Women's Health, Inc. Announces New Data on Phase III Investigational Progesterone Vaginal Ring at the 68th Annual Meeting of the American Society for Reproductive Medicine
- Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting on December 20, 2012
- GlycoMimetics Announces Publication in Nature Medicine of Preclinical Data for Its GMI-1070 Drug Candidate
- New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient (Prasugrel) or Plavix (Clopidogrel) Presented at TCT
- Posiphen Restores Brain Function, Cognition and Memory in Transgenic Alzheimer Mice
- Phase IIa Laquinimod Trial Results Show Positive Data for Potential Use in Active Crohn's Disease
- Merck Announces Results From New Phase III Study Amongst Women for Corifollitropin Alfa, an Investigational Fertility Treatment for Controlled Ovarian Stimulation
- Legacy Healthcare announces breakthrough clinical results in hair re-growth
- Rhythm Announces Positive Phase 1 Results for Ghrelin Prokinetic RM-131
- New Data Support Use Of PROMETHEUS Anser IFX Assay In Managing infliximab Treatment Failure Among Inflammatory Bowel Disease Patients
October 24, 2012
- Positive Results from Phase 2b Study of Ophthotech's Novel Anti-PDGF Combination Agent Fovista? To Be Presented at AAO Retina Subspecialty Day
- Elixir Medical Corporation Announces Outstanding Three-Year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne System
- ARIAD Announces U.S. Food and Drug Administration Acceptance of NDA Filing for Ponatinib
- Bayer's Investigational Riociguat Meets Primary Endpoint in Phase III Study of Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
- United Therapeutics Announces Receipt Of Complete Response Letter For Oral Treprostinil NDA
- Reported at TCT 2012: InspireMD MGuard Stent Meets Primary Endpoint of MASTER Trial, Significantly Improving Prospects of Heart Attack Survival
- VAP Lipid Panel is Highlighted in Scientific Presentations at 2012 American Heart Association Scientific Sessions
- Acusphere Announces Submission of Marketing Authorisation Application for Imagify in Europe and Start of Procedural Review
- Enlivex Therapeutics Announces Positive Results in Completion of Clinical Trial for the Treatment of Bone Marrow Transplant Recipients
- TxCell announces publication of CATS1 study results for antigen-specific Treg therapy in Crohn?s disease in Gastroenterology
- Anti-Cocaine Vaccine Combined with Immunovaccine?s DepoVax Shows Promise in Exploratory Study
- The International Myeloma Foundation Says Investigational Drug Pomalidomide Shows Overall Survival in Patients with Multiple Prior Treatments
- Actinium Pharmaceuticals Announces First Place for Actimab-A Poster Presentation at the 8th Annual Hematologic Malignancies 2012 Conference
- Myeloma Canada Says Pomalidomide Study Shows Overall Survival in Late-Stage Clinical Trial
- Teva Women's Health, Inc. Announces for the First Time Results of Pivotal Phase III Study of Quartette (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets) at the 68th Annual Meeting of ASRM
- Pomalidomide, Being Tested for Multiple Myeloma, Improves Overall Survival in Patients in a Clinical Trial
- Alvine Pharmaceuticals Presents Celiac Disease Symptom Frequency and Severity Study Results at the 2012 American College of Gastroenterology Meeting
- SAPPHIRE Worldwide Study Data Presented at TCT 2012
October 25, 2012
- Acceleron's ACE-536 Corrects Anemia and Iron Overload in Preclinical Model of Beta-Thalassemia
- Amarantus BioSciences Announces MANF Demonstrates Superiority over GDNF in Neurorestoration Behavioural Animal Model of Parkinson's Disease
- ABRAXANE Demonstrates Significant Improvement in Progression-Free Survival Compared to Standard Chemotherapy in Advanced Melanoma Patients
- ABRAXANE Demonstrates Significant Improvement in Progression-Free Survival Compared to Standard Chemotherapy in Advanced Melanoma Patients
- 8500+ Patient Trial Validates Association between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012
October 26, 2012
- More Women are Dying From Lung Cancer Than Ever Before, Despite Falling Cancer Rates Across the UK
- Galena Biopharma Reports Clinical Biomarker Data Demonstrating the Role of NeuVax in Preventing Breast Cancer Recurrence
- Columbia Laboratories Confirms FDA Denies Watson's Appeal Related to Prochieve NDA for the Prevention of Preterm Birth
- Analysis of Large Clinical Trial Database Shows Atorvastatin (Lipitor) to be Well Tolerated by the Asian Population
- Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
- Galectin Therapeutics to Present New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012
October 29, 2012
- Arrowhead Presents Data Showing 99% Target Knockdown in Monkeys Without Toxicity Using Subcutaneous Formulation of Dynamic Polyconjugate siRNA Delivery System
- XBiotech Reports Positive Phase II Interim Analysis Results From Type 2 Diabetes Study
- Celldex Therapeutics Makes Significant Advancements in the Field of Protein-Based Vaccine Development
- Novel, Oral Drug TTP488 Shows Promise for Disease Modification in Alzheimer's Patients
- Beactica Contributes to Detailed Understanding of Innovative Cancer Drug
- Provectus Presents Nonclinical Data on Antitumor Immune Response to PV-10 Immuno-Chemoablation
- Sildenafil Citrate Improves Overall Sexual Function of Prostate Cancer Patients Receiving Radiation Therapy
- Visterra presents prophylactic and therapeutic efficacy data of VIS410 against the H5N1 (Avian Flu) influenza strain in Hanoi, Viet Nam
- Provectus Presents Nonclinical Data on Antitumor Immune Response to PV-10 Immuno-Chemoablation
